Hello!
To view this content, please sign up or log in – it’s free and easy! Stay ahead with curated regulatory insights designed for professionals like you.
Brief
"On November 27, 2024, the Medicines and Healthcare products Regulatory Agency (MHRA) approved flortaucipir (Tauvid), a radiopharmaceutical product for adults with memory problems. This approval enables doctors to perform PET scans to determine if patients have abnormal forms of tau protein in their brain, which is associated with Alzheimer's disease."
Highlights content goes here...
Hello!
To view this content, please sign up or log in – it’s free and easy! Stay ahead with curated regulatory insights designed for professionals like you.
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested
